Clinical ink
Share on
CONTACT US: 1.336.714.7402


Presented by:
Clinical Ink President and Co-Founder Doug Pierce
Clinical Ink VP, Outcome Solutions Kyle Hogan


Only one systemic lupus erythematosus (SLE)-specific drug has been approved. Ever. Why? For sponsors and CROs, recruiting the right patients and collecting quality data for lupus clinical trials are both notoriously difficult.

This webinar explains why lupus research is so complex and discusses a new, disease-specific application of Lumenis™ called eLAS™. This integrative, powerful form of electronic clinical outcome assessment (eCOA) addresses the fundamental challenges and idiosyncrasies of SLE research to accelerate the development of new treatments for this underserved group of patients.

Topics covered include:

  • How diagnostic criteria for SLE research are more stringent than typical in-office criteria, leading to a high rate of screening failures
  • How (and why) even experienced researchers often have difficulty documenting SLE research data correctly
  • How carefully programmed workflows in the eLAS handle the multiple, complex, duplicative, and contradictory questionnaires that form the backbone of SLE research — and how the eLAS system eliminates the data inconsistencies that often occur
  • How real-time edit checks and pop-up data entry reminders can minimize queries
  • Other efficiency advantages, such as automatic data sharing from one questionnaire to another, a web portal for easy visibility, and ways to enter a wide variety of data types into the electronic research file


While this webinar focuses on lupus, the right, carefully designed eCOA application can vastly reduce site workload and improve site performance, data quality, and the overall likelihood of successful study completion for any complex trial type. Specific platforms for other areas, such as GI, CNS, oncology, and dermatology are available or under development.

Download & Read this Resource Now